Plasma microRNA profile as a predictor of early virological response to interferon treatment in chronic hepatitis B patients

Antiviral Therapy

Volumn 17, Issue 7, 2012, Pages 1243-1253

  Zhang, Xiaonan ^a   Chen, Cuncun ^a,b   Wu, Min ^a   Chen, Liang ^a   Zhang, Jiming ^c   Zhang, Xinxin ^d   Zhang, Zhanqin ^a   Wu, Jingdi ^a   Wang, Jiefei ^a   Chen, Xiaorong ^a   Huang, Tao ^e   Chen, Lixiang ^a   Yuan, Zhenghong ^a,b  

^a FUDAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c FUDAN UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

^e Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA1 INTERFERON; ALPHA1B INTERFERON; ALPHA2B INTERFERON; INTERFERON; LET 7F; MICRORNA; MICRORNA 638; MICRORNA 939; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; JACKKNIFE TEST; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; SUPPORT VECTOR MACHINE;

ADULT; ALANINE TRANSAMINASE; BIOPSY; CELL LINE; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; LOGISTIC MODELS; MALE; MICRORNAS; MIDDLE AGED; ODDS RATIO; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870527046     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2401     Document Type: Article

References (31)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107. (Pubitemid 38365759)
2. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695. (Pubitemid 41007823)
3. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48 Suppl 1:S2-S19.
4. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17:643-650.
5. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137:2002-2009.
6. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101:297-303. (Pubitemid 43381671)
7. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52:454-461.
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-297.
9. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18:997-1006.
10. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009; 106:4402-4407.
11. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105:10513-10518.
12. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, Witten IH. The WEKA data mining software: an update. SIGKDD Explor 2009; 11:10-18.
13. Huang T, Cui W, Hu L, Feng K, Li YX, Cai YD. Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles. PLoS ONE 2009; 4:e8126.
14. Naito H, Hayashi S, Abe K. Rapid and specific genotyping system for Hepatitis B Virus Corresponding to Six Major Genotypes by PCR using type-specific primers. J Clin Microbiol 2001; 39:362-364. (Pubitemid 32059621)
15. Xiong W, Wang X, Liu X, Xiang L, Zheng L, Yuan Z. Interferon-inducible MyD88 protein inhibits hepatitis B virus replication. Virology 2004; 319:306-314. (Pubitemid 38251271)
16. Xi Y, Nakajima G, Gavin E, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007; 13:1668-1674. (Pubitemid 47481675)
17. Li J, Lin S, Chen Q, et al. Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S/S RNAs. J Virol 2010; 84:6387-6399.
18. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113:1660-1667. (Pubitemid 27461254)
19. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46:562-568. (Pubitemid 30305823)
20. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123-129. (Pubitemid 40091801)
21. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128:1437-1444. (Pubitemid 40712193)
22. Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007; 46:1548-1563. (Pubitemid 350155537)
23. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105:7034-7039. (Pubitemid 351754525)
24. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
25. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
26. Murakami Y, Tanaka M, Toyoda H, et al. Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Med Genomics 2010; 3:48.
27. Ohshima K, Inoue K, Fujiwara A, et al. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS ONE 2010; 5:e13247.
28. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 2010; 38:7248-7259.
29. Han J-F, Ruan Z-H, Zhang B, Wu Y-Z. Differential MicroRNA expression profile of HepG2 cells induced by HBV integration. J Third Military Med Uni 2007; 29:2128-2130.
30. Wang Y, Lu Y, Toh ST, et al. Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J Hepatol 2010; 53:57-66.
31. Sonneveld MJ, Wong VW, Woltman AM, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012; 142:513-520.